GREAT NECK, N.Y.--(BUSINESS WIRE)--Neogenix Oncology, Inc. (Neogenix) announced today that it has acquired substantially all of the assets of International Bio Immune Systems, Inc. (IBS), including several patent applications and patents that will expand the Neogenix intellectual property portfolio, and enhance the opportunity for developing additional therapeutics and diagnostics beyond what is currently in development.
